伯舒替尼Bosutinib(SKI-606) Src/Abl抑制剂|CAS 380843-75-4（53267ES）

Bosutinib (SKI-606, SKI606)，也称伯舒替尼，是一种新型的双重酪氨酸激酶Src/Abl抑制剂，IC₅₀分别为1.2 nM和1 nM，表现出抗癌活性，常用于治疗慢性粒细胞性白血病(CML)。此外，Bosutinib能促进自噬，抑制ERK和STAT3的磷酸化。

参考文献

1. Boschelli DH, et al. Optimization of 4-phenylamino-3-quinolinecarbonitriles as potent inhibitors of Src kinase activity. J Med Chem. 2001 Nov 8;44(23):3965-77.
2. Golas JM, et al. SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. Cancer Res. 2003 Jan 15;63(2):375-81.
3. Vultur A, et al. SKI-606 (bosutinib), a novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells. Mol Cancer Ther. 2008 May;7(5):1185-94.

冰袋运输。粉末直接保存于-20℃，有效期3年。建议分装后-20℃干燥保存，避免反复冻融。